Now available directly to patients, MyPhenome is the first and only precision obesity test that goes beyond GLP-1 treatment response...
Now available directly to patients, MyPhenome is the first and only precision obesity test that goes beyond GLP-1 treatment response...
Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-makingExpands partnering efforts with global pharmaceutical...
Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-makingExpands partnering efforts with global pharmaceutical...
The new 'virtual biopsy' model predicts brain activity, therapy response, and side effects in patients with up to 3x greater...
Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and...
With Support from Google.org, Helps Youth and Young Adults to Co-Create Digital Safety Solutions and Advocate for Community WellbeingALTADENA, Calif.,...
The $400,000 prize honors five researchers who developed the first medical device to generate a human sense through a direct...
Harvard neuroscientist tells the D.C. Circuit that expanding marijuana access without fully addressing documented public health risks could have far...
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window ResearchedKennewick, WA, June...
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain...
Cover Image Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer...
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a...
At The Aesthetic MEET, hosted by The Aesthetic Society (ASAPS), leading plastic surgeons explored the critical role of tension management...
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with...
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorderFive...
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not...
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents...